Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Tau biomarkers

Topic: Brain proteins, microglia and lab models

Plain-language summary

Objective To determine changes of cerebrospinal fluid (CSF) biomarkers of patients on monotherapy with lopinavir/ritonavir. Design The Monotherapy Switzerland/Thailand study (MOST) trial compared monotherapy with ritonavir-boosted lopinavir with continued therapy. The trial was prematurely stopped due to virological failure in six patients on monotherapy.

What this study adds

Evidence grade: Low

This is a trial. This study looked at cerebrospinal fluid markers, including the astrocytic marker S100B, in HIV-infected patients taking lopinavir/ritonavir monotherapy, a trial stopped early because of virological failure. It concerns HIV brain markers, not Alzheimer's disease, so it has no direct implications for treating, curing or preventing Alzheimer's.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Du Pasquier, R. A., Jilek, S., Kalubi, M., Yerly, S., Fux, C. A., Gutmann, C., et al. (2013). Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy. AIDS (London, England). https://doi.org/10.1097/qad.0b013e32835a9a4a

Vancouver

Du Pasquier RA, Jilek S, Kalubi M, Yerly S, Fux CA, Gutmann C, et al. Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy. AIDS (London, England). 2013. doi:10.1097/qad.0b013e32835a9a4a. PMID: 23032410.

BibTeX

@article{dupasquier2013-23032410,
  author  = {Du Pasquier, R. A. and Jilek, S. and Kalubi, M. and Yerly, S. and Fux, C. A. and Gutmann, C. and Cusini, A. and Günthard, H. F. and others},
  title   = {{Marked increase of the astrocytic marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy}},
  journal = {AIDS (London, England)},
  year    = {2013},
  doi     = {10.1097/qad.0b013e32835a9a4a},
  pmid    = {23032410},
  url     = {https://doi.org/10.1097/qad.0b013e32835a9a4a}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This study looked at cerebrospinal fluid markers, including the astrocytic marker S100B, in HIV-infected patients taking lopinavir/ritonavir monotherapy, a trial stopped early because of virological failure. It concerns HIV brain markers, not Alzheimer's disease, so it has no direct implications for treating, curing or preventing Alzheimer's.

Study details

How this study scored 52/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 3 of 4; Study design 11 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 1 of 2; Times cited 3 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 3 of 4; Institution's track record 1 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 52 of 100.52 of 100 points earned48 not earned

Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for sample size and effect reported because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (AIDS (London, England))
Journal's citation record 3 / 4 AIDS: journal h-index 267 (OpenAlex, 2026-10-29)
Study design 11 / 12 A randomized controlled trial (from PubMed type “Randomized Controlled Trial”)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2013 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (pubmed indexes it as a clinical or observational study)
Randomized / blinded 1 / 2 Randomized (as stated in the record)
Times cited 3 / 7 Cited 25 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.7 citations a year over 15 year(s) since 2013
Impact for its field and year 2 / 6 Cited 1.6× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 3 / 4 Last-listed author Pietro Luigi Vernazza: h-index 80 (OpenAlex, whole career)
Institution's track record 1 / 3 University of Zurich: institution h-index 1,220 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 10 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 23032410)
Free to read 0 / 2 Behind a paywall — scores zero
Total 52 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Tau biomarkers from nearby years

Also tagged “cerebrospinal”

820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Tau biomarkers

See all studies in Tau biomarkers →